Graham Capital Management, L.P. Aldeyra Therapeutics, Inc. Transaction History

Graham Capital Management, L.P.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 22, 2023	BUY	$6.11 - $8.16 $61,851 - $82,603	10,123 New	10,123 $67,000
Q3 2022 Nov 14, 2022	SELL	$3.8 - $7.74 $3,021 - $6,153	-795 Reduced 1.88%	41,590 $222,000
Q2 2022 Aug 15, 2022	BUY	$2.43 - $4.85 $102,995 - $205,567	42,385 New	42,385 $169,000
Q1 2022 May 16, 2022	SELL	$3.25 - $5.17 $32,652 - $51,942	-10,047 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$3.5 - $9.63 $35,164 - $96,752	10,047 New	10,047 $40,000

116

36.4M

196K

142K

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $298M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

Get notified when there are updates to the investment portfolio of Graham Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Graham Capital Management, L.P. with notifications on news.